Chairman and CEO of Medco Inc. David Snow

Mike Segar / Reuters

Dealtalk: No biotech too large to buy?

No biotech company is too big to be bought, at least according to one veteran healthcare executive.

Xoma Could Initiate Pivotal Behcet’s Trial by Year-End 2011: Analyst

RBC Capital Markets said Xoma Ltd. (NASDAQ: XOMA) continues to make steady albeit measured progress toward initiating a pivotal trial in Behcet’s disease, which could begin by year-end 2011, pending regulatory feedback.

Week Ahead in Life Sciences

Wedbush Securities said that among the companies it covered in Life Sciences this week Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) are reporting earnings.

Cash Runway Expected for Xoma Through Start of Phase 3 Behcet's Uveitis Study: Analyst

Wedbush Securities expects cash runway for XOMA Ltd. (NASDAQ: XOMA) through start of phase 3 Behcet’s Uveitis study by year-end 2011.

Seattle Genetics drug gets priority FDA review

The U.S. Food and Drug Administration will review a Seattle Genetics Inc experimental drug for two types of lymphoma on a priority basis, the company said on Monday.

IPO

Formula One Gets Greenlight for $3 Billion Flotation

09:53 AM ET

Media sources say that motor racing giant Formula One has gained approval for an initial public offering worth nearly $3bn on Singapore's stock exchange.